← Leaderboards
Steven G. Reed
Infectious Disease Research Institute
$15,502,031
Attributed
$15,502,031
Total exposure
9
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $5.1M · FY2005–24$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$15,502,031 · 9
By mechanism
R01$9,309,447 · 2
UC1$4,095,564 · 1
R61$1,632,094 · 1
R44$352,372 · 1
R03$78,040 · 1
RC1$26,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Vaccine Development”
- Lawrence Corey · Fred Hutchinson Cancer Center$718,120,301
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$554,939,981
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$394,383,754
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$392,263,550
- Dennis R. Burton · Scripps Research Institute$312,611,400
Research focus
Vaccine DevelopmentImmune ResponseImmunizationT-LymphocyteAntigensImmunogenicityAdjuvantVaccinesResponseTuberculosis VaccinesTuberculosisLeishmaniasisLaboratory MousePreventCellular ImmunityBaseChimeric ProteinsEvaluationInfectionAnimal ModelRecombinant ProteinsMycobacterium TuberculosisVaccine CandidateT Lymphocyte
Grant awards (30)
RNA Vaccine Innovations for TB: Targeting the Mucosa$543,301
R61 · FY2024 · AI · contact PI
RNA Vaccine Innovations for TB: Targeting the Mucosa$538,074
R61 · FY2023 · AI · contact PI
RNA Vaccine Innovations for TB: Targeting the Mucosa$550,719
R61 · FY2022 · AI · contact PI
Leishmania antigens defined by human immune responses$405,674
R01 · FY2016 · AI · contact PI
Leishmania antigens defined by human immune responses$473,205
R01 · FY2015 · AI · contact PI
Leishmania antigens defined by human immune responses$481,424
R01 · FY2014 · AI · contact PI
Leishmania antigens defined by human immune responses$370,817
R01 · FY2013 · AI · contact PI
Leishmania antigens defined by human immune responses$468,985
R01 · FY2012 · AI · contact PI
Human T Cell Antigens of Mycobacterium tuberculosis$483,474
R01 · FY2009 · AI · contact PI
Leishmania Antigens Defined by Human Immune Responses$639,876
R01 · FY2008 · AI · contact PI
Human T Cell Antigens of Mycobacterium tuberculosis$470,628
R01 · FY2008 · AI · contact PI
Leishmania Antigens Defined by Human Immune Responses$633,273
R01 · FY2007 · AI · contact PI
Human T Cell Antigens of Mycobacterium tuberculosis$467,034
R01 · FY2007 · AI · contact PI
Leishmania Antigens Defined by Human Immune Responses$621,488
R01 · FY2006 · AI · contact PI
Human T Cell Antigens of Mycobacterium tuberculosis$468,275
R01 · FY2006 · AI · contact PI
GLOBAL ANALYSIS OF PROTEIN SUMOYLATION IN SACCHAROMYCES CEREVISIAE$2,859
P41 · FY2006 · RR · contact PI
Development &Manufacture of an MDR Tuberculosis Vaccine$4,095,564
UC1 · FY2005 · AI
Leishmania Antigens Defined by Human Immune Responses$551,120
R01 · FY2005 · AI
Human T Cell Antigens of Mycobacterium tuberculosis$397,752
R01 · FY2005 · AI
GLOBAL ANALYSIS OF PROTEIN SUMOYLATION IN SACCHAROMYCES CEREVISIAE$5,655
P41 · FY2005 · RR
Leishmania Antigens Defined by Human Immune Responses$536,093
R01 · FY2004 · AI
HUMAN T CELLS ANTIGENS OF MYCOBACTERIUM TUBERCULOSIS$378,081
R01 · FY2003 · AI
HUMAN T CELLS ANTIGENS OF MYCOBACTERIUM TUBERCULOSIS$332,888
R01 · FY2002 · AI
HUMAN T CELLS ANTIGENS OF MYCOBACTERIUM TUBERCULOSIS$356,486
R01 · FY2001 · AI
LEISHMANIA ANTIGENS DEFINED BY HUMAN IMMUNE RESPONSES$39,020
R03 · FY2001 · TW
LEISHMANIA ANTIGENS DEFINED BY HUMAN IMMUNE RESPONSES$426,721
R01 · FY2000 · AI
VACCINE FOR LEISHMANIASIS$352,372
R44 · FY2000 · AI
HUMAN T CELLS ANTIGENS OF MYCOBACTERIUM TUBERCULOSIS$346,153
R01 · FY2000 · AI
LEISHMANIA ANTIGENS DEFINED BY HUMAN IMMUNE RESPONSES$39,020
R03 · FY2000 · TW
DEVELOPMENT OF A RECOMBINANT TUBERCULOSIS VACCINE$26,000
RC1 · FY2000 · AI